Sempra (SRE) concluded trading on Thursday at a closing price of $74.94, with 4.42 million shares of worth about $331.51 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -13.67% during that period and on June 26, 2025 the price saw a loss of about -0.11%. Currently the company’s common shares owned by public are about 651.93M shares, out of which, 651.57M shares are available for trading.
Stock saw a price change of 0.74% in past 5 days and over the past one month there was a price change of -5.03%. Year-to-date (YTD), SRE shares are showing a performance of -1.98% which decreased to -14.57% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $61.90 but also hit the highest price of $95.77 during that period. The average intraday trading volume for Sempra shares is 4.26 million. The stock is currently trading -1.18% below its 20-day simple moving average (SMA20), while that difference is down -0.63% for SMA50 and it goes to -6.64% lower than SMA200.
Sempra (NYSE: SRE) currently have 651.93M outstanding shares and institutions hold larger chunk of about 89.83% of that.
The stock has a current market capitalization of $48.87B and its 3Y-monthly beta is at 0.65. PE ratio of stock for trailing 12 months is 16.49, while it has posted earnings per share of $4.54 in the same period. Its PEG reads 3.20 and has Quick Ratio of 0.51 while making debt-to-equity ratio of 1.19. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SRE, volatility over the week remained 1.77% while standing at 1.86% over the month.
Stock’s fiscal year EPS is expected to drop by -3.02% while it is estimated to increase by 10.60% in next year. EPS is likely to grow at an annualized rate of 5.15% for next 5-years, compared to annual growth of 3.92% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on April 09, 2025 offering a Neutral rating for the stock and assigned a target price range of between $93 and $70 to it. On March 03, 2025, Jefferies Downgrade their recommendations, while on February 27, 2025, Barclays Downgrade their ratings for the stock with a price target of $72. Stock get a Neutral rating from UBS on February 26, 2025.
